Radioimmunotherapy with 131I-anti-CD20 rituximab in B-cell lymphoma: Results of the goettingen RAIT study group.

被引：0
|
作者：
Griesinger, F
Behr, T
Jung, W
Glass, B
Truemper, LH
Meller, J
Woermann, B
Kaufmann, CC
Binder, C
Brittinger, G
Becker, W
机构：
[1] Univ Gottingen, D-3400 Gottingen, Germany
[2] Univ Marburg, Marburg, Germany
[3] Braunschweig Hosp, Braunschweig, Germany
[4] Hosp Wyk AF, Wyk Foehr, Schleswig Holstein, Germany
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4795
引用
收藏
页码：313B / 313B
页数：1
相关论文
共 50 条
  • [1] Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma:: Final results of a phase II study of the German Rait Study Group
    Hohloch, K.
    Lakhani, V.
    Sahlmann, C.
    Wulf, G.
    Jung, W.
    Glass, B.
    Meller, J.
    Truemper, L.
    Griesinger, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 184 - 184
  • [2] RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY
    KAMINSKI, MS
    ZASADNY, KR
    FRANCIS, IR
    MILIK, AW
    ROSS, CW
    MOON, SD
    CRAWFORD, SM
    BURGESS, JM
    PETRY, NA
    BUTCHKO, GM
    GLENN, SD
    WAHL, RL
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (07): : 459 - 465
  • [3] RADIOIMMUNOTHERAPY OF REFRACTORY B-CELL LYMPHOMA WITH 131-I-ANTI-B1 (ANTI-CD20) ANTIBODY
    KAMINSKI, MS
    FENNER, M
    ZASADNY, KR
    MILIK, AW
    ROSS, CW
    FRANCIS, IR
    BURGESS, J
    ESTES, J
    CRAWFORD, S
    HODUL, P
    COOK, R
    REGAN, D
    PETRY, N
    GLENN, S
    BUTCHKO, G
    WAHL, RL
    CLINICAL RESEARCH, 1994, 42 (03): : A405 - A405
  • [4] Radioimmunotherapy (RAIT) with 131I labeled rituximab in patients with CD20+B-cell NHL in a myeloablative regimen
    Schwarz, K
    Schmidt, B
    Scheidhauer, K
    Schwaiger, M
    Peschel, C
    von Schilling, C
    BONE MARROW TRANSPLANTATION, 2001, 27 : S14 - S14
  • [5] Tandem high dose chemotherapy and myeloablative radioimmunotherapy with 131-I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma:: Interim results of a phase II study of the German RIT study group
    Hohloch, K
    Wulf, G
    Glass, B
    Jung, W
    Stitz, E
    Meller, J
    Sahlmann, C
    Trümper, L
    Griesinger, F
    ANNALS OF ONCOLOGY, 2005, 16 : 135 - 135
  • [6] UPDATED RESULTS OF A PHASE-I TRIAL OF 131-I-ANTI-B1 (ANTI-CD20) RADIOIMMUNOTHERAPY (RIT) FOR REFRACTORY B-CELL LYMPHOMA
    KAMINSKI, MS
    ZASADNY, KR
    MILIK, AW
    ROSS, CW
    FRANCIS, IR
    BURGESS, J
    CRAWFORD, S
    ESTES, J
    HODUL, P
    COOK, R
    REGAN, D
    PETRY, N
    GLENN, S
    BUTCHKO, G
    WAHL, RL
    BLOOD, 1993, 82 (10) : A332 - A332
  • [7] High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab
    Becker, W
    Behr, T
    ANNALS OF HEMATOLOGY, 2001, 80 : B130 - B131
  • [8] High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab
    W. Becker
    Th. Behr
    Annals of Hematology, 2001, 80 (Suppl 3) : B130 - B131
  • [9] High-dose radioimmunotherapy in refractory B-cell non-Hodgikin lymphoma with I-131-labeled chimeric anti CD-20 (I-131 rituximab): pilot trial
    Cheon, G.
    Kim, S.
    Park, Y.
    Choi, C.
    Lim, S.
    Lee, S.
    Ryu, B.
    Yang, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S205 - S205
  • [10] Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with 131I-anti-CD20 antibody and stem cell rescue
    Hohloch, Karin
    Sahlmann, Carsten Oliver
    Lakhani, Vijai J.
    Wulf, Gerald
    Glass, Bertram
    Hasenkamp, Justin
    Meller, Johannes
    Riggert, Joachim
    Truemper, Lorenz
    Griesinger, Frank
    ANNALS OF HEMATOLOGY, 2011, 90 (11) : 1307 - 1315
12345